Contents lists available at ScienceDirect

Heliyon



journal homepage: www.cell.com/heliyon

Review article

CelPress

Exploring the risk of infection events in patients with asthma receiving *anti*-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis

Riccardo Giossi^a, Arianna Pani^{b,*}, Jan Schroeder^c, Francesco Scaglione^{a,b}

^a Chemical-Clinical Analyses Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

^b Department of Oncology and Hemato-Oncology, Università Degli Studi di Milano, Milan, Italy

^c Allergology and Immunology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

ARTICLE INFO

Keywords: Benralizumab Mepolizumab Reslizumab IL-5 Infection Meta-analysis

ABSTRACT

Introduction: Benralizumab, mepolizumab, and reslizumab are novel monoclonal antibodies approved for asthma, targeting eosinophilic inflammation. Benralizumab is directed against IL-5 receptor (IL-5R), while mepolizumab and reslizumab are directed against IL-5. The three drugs cause a reduction in eosinophils, but benralizumab also causes a cytotoxic effect on eosinophils and basophils. Recently, it has been reported that suboptimal responders to benralizumab presented exacerbations associated with concomitant infections and sputum neutrophilia and the incidence of infections was greater in patients receiving benralizumab compared to mepolizumab and reslizumab. For this reason, we wanted to explore potential differences in terms of infectious adverse events between the three different *anti*-IL-5 antibodies.

Methods: We performed a rapid systematic review on PubMed up to April 28, 2022. We included randomized controlled trials (RCTs) evaluating benralizumab, mepolizumab, or reslizumab in patients with asthma. Included outcomes were the reporting of any respiratory tract infection and any emergency department (ED) or hospital admission for infection or asthma exacerbation. A Mantel-Haenszel meta-analysis was performed with Cochrane RevMan 5.4 to estimate pooled odds ratios (OR) with 95 % confidence intervals (CI). A subgroup analysis for the different active treatments was performed.

Results: From 163 references we included 21 studies reporting the results of 23 different RCTs for a total population of 9156 patients. All studies compared *anti*-IL-5 antibodies against placebo. *Anti*-IL-5 treatment resulted in non-significant differences compared to placebo in the odds for nasopharyngitis (OR = 0.90; 95 % CI from 0.76 to 1.07), pharyngitis (OR = 1.45; 95 % CI from 0.92 to 2.28), upper respiratory tract infection (URTI) (OR = 0.97; 95 % CI from 0.82 to 1.15), rhinitis (OR = 1.01; 95 % CI from 0.71 to 1.44), pneumonia (OR = 0.56; 95 % CI from 0.10 to 2.01), and influenza (OR = 0.84; 95 % CI from 0.65 to 1.09). We observed significant reductions in the reporting of sinusitis (OR = 0.75; 95 % CI from 0.53 to 1.06), bronchitis (OR = 0.71; 95 % CI from 0.59 to 0.86), and ED or hospital admission due to asthma exacerbation for overall *anti*-IL-5 antibodies compared to placebo (OR = 0.59; 95 % CI from 0.40 to 0.88). We were not able to discriminate whether exacerbations were associated with infections or to increased sputum eosinophilia. From the subgroup analysis, we observed differences in directions and magnitudes

E-mail address: arianna.pani@unimi.it (A. Pani).

https://doi.org/10.1016/j.heliyon.2023.e23725

Received 21 March 2023; Received in revised form 11 December 2023; Accepted 12 December 2023

Available online 15 December 2023

^{*} Corresponding author. Department of Oncology and Hemato-Oncology, Postgraduate School of Clinical Pharmacology and Toxicology, Università degli Studi di Milano, Milan, Italy.

^{2405-8440/© 2023} The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

of the effect size in the reporting of some events. Benralizumab was associated with increased odds of pharyngitis (OR = 1.56; 95 % CI from 0.97 to 2.52) and a similar trend was observed for mepolizumab in the reporting of rhinitis (OR = 1.85; 95 % CI from 0.72 to 4.78), both non-statistically significant. In terms of effect size, benralizumab also showed higher odds for bronchitis and pneumonia in comparison to mepolizumab and reslizumab (OR = 0.76, OR = 0.69, and OR = 0.60 for bronchitis and OR = 0.80, OR = 0.20, and OR = 0.45, respectively, all non-significant).

Conclusion: Anti-IL-5 treatments might have different effects on the reporting of some infection events in patients with asthma. However, the evidence is limited by sample size and far than conclusive and suggest the need of future studies to evaluate the risk of infections in patients with asthma receiving *anti*-IL-5 treatments.

1. Introduction

Novel treatments for asthma are directed against eosinophilic inflammation by targeting IL-5. IL-5 is a homodimeric cytokine which acts as the primary modulator of eosinophils. In Europe, three monoclonal antibodies directed against IL-5 have been approved. Mepolizumab and reslizumab bind directly to circulating IL-5 and reduce eosinophil counts by inhibiting IL-5 signalling. Benralizumab, on the other hand, is a monoclonal antibody directed against the IL-5 receptor (IL-5R) alpha chain with a cytotoxic effect capable of completely depleting the eosinophilic as well as basophilic population [1].

The role of eosinophils in relation to the pathophysiology of asthma has been extensively discussed in the literature [2]. A high eosinophil count is associated with more disease severity [3]. Eosinophils accumulate in the lungs in the inflammatory setting causing tissue damage and promoting Th2-mediated inflammatory signalling [4].

On the other hand, the role of eosinophils in protecting the body from infection remains debated. Traditionally, the function of eosinophils has traditionally been associated with protection against parasitic infections. However, studies have also shown they are involved in fungal [5,6] and viral infections [7]. For example, it has recently been reported that eosinopenia is linked with acute respiratory deterioration during SARS-CoV2 infection [8,9]. Other studies associated eosinopenia with poor outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) [10] and identified eosinopenia as a possible marker of severe infection and sepsis [11].

A recent prospective cohort study reported a suboptimal response, namely the presence of exacerbations or failure to reduce prednisone by at least 50 %, in about 27 % of patients receiving benralizumab. Authors found that only a minority of exacerbations in this group of patients were associated with sputum eosinophilia. Conversely, the majority of them were associated with concomitant infections and sputum neutrophilia. Also, the incidence of respiratory infections increased in the assessed population while receiving benralizumab and was significantly greater compared to that observed in a group of patients receiving mepolizumab or reslizumab [12].

Given these observations, we decided to conduct a rapid systematic review and a meta-analysis including randomized controlled trials (RCTs) evaluating *anti*-IL-5 monoclonal antibodies for asthma to explore potential differences in terms of the reporting of infectious adverse events.

2. Methods

2.1. Search strategy and selection criteria

We performed a literature search on PubMed from the beginning up to August 28, 2023 to include RCTs fulfilling our inclusion criteria. The search strategy included "benralizumab", "mepolizumab", "reslizumab", "asthma", and "RCTs" as keywords used as MeSH and free terms and combined with Boolean operators (Supplementary Material S1). We included full-text English articles reporting data of RCTs, in patients with asthma of any age, evaluating benralizumab, mepolizumab, or reslizumab against placebo or any active comparator. Observational studies, case series, case reports, reviews, editorials, commentaries, congress abstracts, and study with no outcomes were excluded. Two study authors (R.G. and A.P.) independently screened literature citations for inclusion and discrepancies were resolved by collegial discussion.

2.2. Assessed outcomes

Included outcomes of our systematic review were the reporting of any respiratory tract infection coded according to the MedDRA dictionary. Infection events were collected separately for each available category from included RCTs. Additional outcomes were emergency department (ED) or hospital admission for infection and ED or hospital admission asthma exacerbation. Respiratory tract infections were defined as upper respiratory tract infections (URTI), including nasopharyngitis, pharyngitis, sinusitis, acute sinusitis, and rhinitis and lower respiratory tract infections (LRTI), such as bronchitis, pneumonia, and influenza.



Fig. 1. PRISMA flow diagram.

2.3. Data extraction

Two study authors (R.G. and A.P.) independently extracted included study data on an Excel spreadsheet and discrepancies were resolved by discussion. Extracted data consisted in: first author, year, period, study duration, patients age and sex, RCTs main inclusion and exclusion criteria, total patient included, the different treatment and *anti*-IL-5 dose regimens, and prespecified included outcomes.

2.4. Statistical analysis

Events from outcomes of interest were collected from included studies. Whenever the number of events was not completely reported, we estimated the number of adverse events from available rates or odds ratios (ORs), confidence intervals (CI), or p-values. For all comparisons, we used a random-effect Mantel-Haenszel meta-analysis performed with Cochrane RevMan 5.4 software. Heterogeneity was evaluated with the I-squared statistic. Pooled estimates were reported as ORs and 95%CI. A subgroup analysis was

Table 1

4

Included studies characteristics.

| Author Year | Inclusion criteria | Study duration/phases | Treatment | Comparator | Total population | Female, N | Steroids and concurrent therapy management |
|-------------------------------------|---|-----------------------|---|--|---------------------|--------------|--|
| Benralizumah | | | | | | | |
| Laviolette 2013 [13] | M and F, 18 to 65 yo, with eosinophilic asthma, on a stable asthma medication for 4 weeks before screening | 86 to 56+86 days | Benralizumab 1 mg/kg ev once, or 100 or 200 mg in 4 sc injections on days 0, 28 and 56 | Placebo | 27 | 16 | Usual concurrent therapy |
| Castro 2014 [14] | M and F, 18 to 75 yo, with EO or non-EO asthma, with 1 year treatment with ICS/LABA, and two to six exacerbations needing systemic corticosteroids in the last year | 52 w | EO: Benralizumab 2 mg, or 20 mg, or 100 mg; non-EO: Benralizumab 100 mg. Two sc every 4 w for the first 3 doses, then every 8 weeks | EO and non-EO: Placebo | 606 | 417 | Stratification based on medium or high steroid dose |
| Park 2016 [15] | M and F, 20 to 75 yo, with EO asthma, on ICS/ LABA combination, 2–6 exacerbations requiring systemic CS in the past year | 52 w | Benralizumab 2, 20, or 100 mg sc q4w up to w8, then q8w | Placebo | 103 | 65 | Stratification based on medium or high steroid dose |
| FitzGerald 2016 (CALIMA) [16] | M and F, 12 to 75 yo, with asthma, on medium dose ICS/LABA, two or more exacerbations in the last year requiring systemic CS or temporary ioncrease of usual oral CS | 56 w | benralizumab 30 mg q4w, 30 mg q4w for three doses and then q8w | Placebo | 1306 | 807 | Stratification based on medium or high steroid dose |
| Bleecker 2016 (SIROCCO) [17] | M and F, 12 to 75 yo, with asthma, on high dose ICS/LABA, two or more exacerbations in the last year requiring systemic CS or temporary increase of usual oral CS | 48 w | Benralizumab 30 mg q4w, 30 mg q8w | Placebo | 1204 | 796 | Usual concurrent stable therapy |
| Ferguson 2017 (BISE) [18] | M and F, 18 to 75 yo, mild to moderate asthma, low to medium dose ICS or low dose ICS/LABA, night time or daytime asthma symptom score 1+ for 2+ days, or rescue SABA for 2 days, or night time awakenings due to asthma, in the last 7 days | 20 w | Benralizumab 30 mg q4w | Placebo | 211 | 129 | Usual concurrent stable therapy |
| Nair 2017 (ZONDA) [19] | M and F, adult, with asthma and eosinophils more than 150/ μL , on oral CS for 6 months and LABA | 36 w | Benralizumab 30 mg q4w, 30 mg q8w | Placebo | 220 | 135 | Usual concurrent therapy with modifiable CS dose |
| Zeitlin 2018 (ALIZE) [20] | M and F, 12 to 21 yo, with asthma and current regular use of ICS, all receiving quadrivalent influenza vaccine in the trial context | 20 w | Benralizumab 30 mg sc q4w; influenza quadrivalent vaccine | Placebo; influenza quadrivalent vaccine | 103 | 42 | ICS at stable dose |
| Panettieri 2020 (SOLANA) [21] | M and F, 18 to 75 yo, with severe eosinophilic asthma, on ICS/LABA, and two exacerbations requiring systemic CS or increase in maintenance oral CS in the last year | 16 w | Benralizumab 30 mg q4w | Placebo | 233 | 157 | Usual concurrent therapy |
| Harrison 2021 (ANDHI) [22] | M and F, 18 to 75 yo, with severe eosinophilic asthma, on ICS and additional controllers, and two asthma exacerbations in the last year | 24 w | Benralizumab 30 mg q8w | Placebo | 660 | 399 | Usual concurrent stable therapy |

(continued on next page)

Table 1 (continued)

| Author Year | Inclusion criteria | Study duration/phases | Treatment | Comparator | Total population | Female, N | Steroids and concurrent therapy management |
|---------------------------------------|---|---|---|------------|------------------|--------------|---|
| <i>Mepolizumab</i> Flood-Page 2003 | M and F, 18 to 55 yo, with mild asthma and | 20 w | Mepolizumab 750 mg q4w ev | Placebo | 24 | 7 | NO |
| [23] | atopic by prick test to one or more aeroallergens, well controlled with SABA and no use of CS or other anti-inflammatory drugs in the previous 8 weeks | | | | | | |
| Haldar 2009 [24] | M and F, more than 18 yo, with refractory asthma, sputum eosinophil more than 3 % despite high dose steroids, at least 2 exacerbations requiring rescue prednisolone in previous 12 months | 12 months | Mepolizumab 750 mg monthly | Placebo | 61 | 29 | Usual concurrent therapy |
| Pavord 2012 (DREAM) [25] | M and F, 12 to 74 yo, with refractory asthma, evidence of eosinophilic inflammation, two or more exacerbations requiring systemic CS in the previous year, treated with inhalatory steroids and requiring additional controller drugs. | 52 w | Mepolizumab 75/250/750 mg monthly | Placebo | 616 | 393 | Stable treatment of at least 880 µg fluticasone propionate equivalent per day, with or without maintenance oral CS, and additional controller drugs |
| Ortega 2014 (MENSA) [26] | M and F, 12 to 82 yo, with eosinophilic asthma, two or more exacerbations requiring systemic CS in the previous year while on 880 μ g fluticasone or equivalent and an additional controller | 1-6 w run-in; 32 w treatment - 8 w safety | Mepolizumab 75 mg ev, or 100 mg sc every 4 w | Placebo | 576 | 329 | Usual concurrent therapy |
| Bel 2014 (SIRIUS) [27] | M and F, 12 yo or older, with eosinophilic severe asthma, six months maintenance treatment with inhaled and systemic steroids and an additional controller | Glucocorticoid optimization; Randomization and induction 4 w; glucocorticoid reduction 16 w; maintenance 4 w; final safety at week 32 | Mepolizumab 100 mg sc | Placebo | 135 | 74 | Optimized dose |
| Chupp 2017 (MUSCA) [28] | M and F, 12 yo or older, with eosinophilic asthma, on high dose ICS plus other controllers, and at least two exacerbations requiring treatment in the last year | 24 w | Mepolizumab 100 mg sc | Placebo | 556 | 325 | Usual concurrent therapy; only 25 % with maintenance OS |
| Reslizumab | | | | | | | |
| Castro 2011 [29] | M and F, 18 to 75 yo, with poorly controlled asthma, receiving high-dose ICS and at least one other agent | 15 w | Reslizumab 3,0 mg/kg | Placebo | 106 | 63 | High-dose ICS (\geq 440 µg of fluticasone twice per day) in combination with at least one other agent |
| Castro 2015 (Study 1) [30] | M and F, 12 to 75 yo, with eosinophilic asthma, on ICS with or without another controller, and at least one exacerbation requiring systemic steroids in the last year | 52 w treatment and last visit 90 days after EOT | Reslizumab 3,0 mg/kg q4w | Placebo | 489 | 303 | Usual concurrent therapy |

(continued on next page)

Table 1 (continued)

| Author Year | Inclusion criteria | Study duration/phases | Treatment | Comparator | Total population | Female, N | Steroids and concurrent therapy management |
|----------------------------------|--|---|---|------------|---------------------|--------------|--|
| Castro 2015 (Study 2) [30] | M and F, 12 to 75 yo, with eosinophilic asthma, on ICS with or without another controller, and at least one exacerbation requiring systemic steroids in the last year | 52 w treatment and last visit 90 days after EOT | Reslizumab 3,0 mg/kg q4w | Placebo | 464 | 294 | Usual concurrent therapy |
| Bjermer 2016 [31] | M and F, 12 to 75 yo, with inadequately controlled eosinophilic asthma, on ICS | 16 w $+$ 4 w follow up | Reslizumab 0,3 mg/kg or 3,0 mg/kg q4w ev | Placebo | 315 | 174 | Usual concurrent therapy |
| Corren 2016 [32] | M and F, 18 to 65 yo, with inadequately controlled asthma (patients were not selected on the basis of eosinophyls), on ICS | 16 w treatment + 12 w follopw up | Reslizumab 3.0 mg/kg ev q4w | Placebo | 496 | 315 | Usual concurrent therapy |
| Bernstein 2020 (Study 1) [33] | M and F, 12 yo or older, with eosinophilic asthma, on medium-dose ICS and at least one other controller, and two exacerbations requiring systemic CS in the last year | 52 w | Reslizumab 110 mg q4w | Placebo | 468 | 308 | ICS, some OS |
| Bernstein 2020 (Study 2) [33] | M and F, 12 yo or older, with eosinophilic asthma, on medium-dose ICS and a daily maintenance OCS, at least 6 months high-dose ICS in the six months before screening at least one other controller, and two exacerbations requiring systemic CS in the last year | 24 w | Reslizumab 110 mg q4w | Placebo | 177 | 145 | OS all concurrent; stratified based on steroid dose; with modifiable CS dose |

Abbreviations: CS = corticosteroids; EO = eosinophilic; ICS = inhalatory corticosteroids; LABA = long-acting beta agonists; SABA = short-acting beta agonists.

| | Anti-IL-5 | | Placebo | | Odds Ratio | | | Odds Ratio | | |
|---|-------------------------|----------|------------|-----------------------|---------------|---------------------|------|---|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | |
| 1.1.1 Benralizumab | | | | | | | | | | |
| Laviolette 2013 | 4 | 17 | 4 | 10 | 0.9% | 0.46 [0.09, 2.50] | 2013 | · · · · · · · · · · · · · · · · · · · | | |
| Castro 2014 | 68 | 385 | 21 | 221 | 7.5% | 2.04 [1.21, 3.44] | 2014 | | | |
| FitzGerald 2016 (CALIMA) | 169 | 866 | 92 | 440 | 15.2% | 0.92 [0.69, 1.22] | 2016 | | | |
| Park 2016 | 23 | 77 | 13 | 26 | 3.0% | 0.43 [0.17, 1.06] | 2016 | · · · · · · · · · · · · · · · · · · · | | |
| Bleecker 2016 (SIROCCO) | 93 | 797 | 47 | 407 | 11.6% | 1.01 [0.70, 1.47] | 2016 | _ | | |
| Nair 2017 (ZONDA) | 22 | 145 | 15 | 75 | 4.5% | 0.72 [0.35, 1.48] | 2017 | | | |
| Ferguson 2017 (BISE) | 8 | 106 | 8 | 105 | 2.5% | 0.99 [0.36, 2.74] | 2017 | | | |
| Zeitlin 2018 (ALIZE) | 2 | 51 | 4 | 52 | 0.9% | 0.49 [0.09, 2.80] | 2018 | · · · · · · · · · · · · · · · · · · · | | |
| Panettieri 2020 (SOLANA) | 8 | 118 | 6 | 115 | 2.2% | 1.32 [0.44, 3.93] | 2020 | | | |
| Harrison 2021 (ANDHI) | 30 | 427 | 17 | 229 | 5.8% | 0.94 [0.51, 1.75] | 2021 | | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 54.0 % | 0.97 [0.75, 1.26] | | • | | |
| Total events | 427 | | 227 | | | | | | | |
| Heterogeneity: Tau ² = 0.05; C | hi ² = 13.5 | 2, df= | 9 (P = 0.1 | 4); l ² = | 33% | | | | | |
| Test for overall effect: Z = 0.2 | 1 (P = 0.8 | 3) | | | | | | | | |
| | | | | | | | | | | |
| 1.1.2 Mepolizumab | | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | | |
| Bel 2014 (SIRIUS) | 10 | 69 | 10 | 66 | 2.8% | 0.95 [0.37, 2.45] | 2014 | | | |
| Ortega 2014 (MENSA) | 78 | 385 | 46 | 191 | 10.2% | 0.80 [0.53, 1.21] | 2014 | | | |
| Chupp 2017 (MUSCA) | 31 | 273 | 46 | 278 | 8.2% | 0.65 [0.40, 1.05] | 2017 | | | |
| Subtotal (95% CI) | | 1228 | | 735 | 21.2% | 0.75 [0.56, 1.01] | | - | | |
| Total events | 119 | | 102 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 0.69 | , df = 2 | (P = 0.71 | $); ^{2} = 0$ |)% | | | | | |
| Test for overall effect: Z = 1.83 | 7 (P = 0.0 | 6) | | | | | | | | |
| | | | | | | | | | | |
| 1.1.3 Reslizumab | | | | | | | | | | |
| Castro 2011 | 11 | 53 | 5 | 53 | 2.0% | 2.51 [0.81, 7.83] | 2011 | | | |
| Castro 2015 (Study 1) | 38 | 245 | 46 | 243 | 8.6% | 0.79 [0.49, 1.26] | 2015 | | | |
| Castro 2015 (Study 2) | 52 | 232 | 64 | 232 | 10.0% | 0.76 [0.50, 1.16] | 2015 | | | |
| Corren 2016 | 13 | 395 | 5 | 97 | 2.3% | 0.63 [0.22, 1.80] | 2016 | | | |
| Bjermer 2016 | 12 | 206 | 4 | 105 | 1.9% | 1.56 [0.49, 4.97] | 2016 | | | |
| Bernstein 2020 (Study 1) | 0 | 237 | 0 | 231 | | Not estimable | 2020 | | | |
| Bernstein 2020 (Study 2) | 0 | 88 | 0 | 89 | | Not estimable | 2020 | | | |
| Subtotal (95% CI) | | 1456 | | 1050 | 24.8% | 0.89 [0.62, 1.28] | | | | |
| Total events | 126 | | 124 | | | | | | | |
| Heterogeneity: Tau ² = 0.04; C | hi² = 5.28 | , df = 4 | (P = 0.26) | $5); I^2 = 2$ | 24% | | | | | |
| Test for overall effect: Z = 0.63 | 3 (P = 0.5 | 3) | | | | | | | | |
| | | | | | | | | | | |
| Total (95% CI) | | 5673 | | 3465 | 100.0% | 0.90 [0.76, 1.07] | | • | | |
| Total events | 672 | | 453 | | | | | | | |
| Heterogeneity: Tau ² = 0.03; C | hi ^z = 22.0 | 12, df = | 17 (P = 0 | .18); I ^z | = 23% | | | | | |
| Test for overall effect: Z = 1.19 | 9 (P = 0.2 | 3) | | | | | | 0.2 0.3 I Z S Eavours Anti-II -5 Eavours Placebo | | |
| Test for subgroup differences | s: Chi ² = 1 | .66, df | = 2 (P = 0 |).44), l ² | = 0% | | | | | |
| | | | | | | | | | | |

Fig. 2. Nasopharyngitis.

performed based on the different anti-IL-5 to allow comparisons in-between treatments.

2.5. Role of the funding source and ethical considerations

The study was not sponsored and did not receive any funding. Due to the nature of the study on already published data without the involvement of new human participants or animals an IRB approval was not necessary.

3. Results

3.1. Search results and study characteristics

From a total of 168 retrieved references, 110 were excluded by title and abstract and 58 were read in full text. Of these, 37 were excluded with reasons and a final number of 21 studies reporting the results of 23 different RCTs were included (Fig. 1). Of these, 11 RCTs were on benralizumab [13–22], 6 on mepolizumab [23–28], and 6 on reslizumab [29–33], all compared to placebo. The total number of patients was 9156 across all included studies and 12 studies enrolled also paediatric patients from the age of 12 years. Benralizumab was administered to 2992 patients; 1231 patients received mepolizumab, 1462 reslizumab, and 3471 a placebo. Included studies characteristics are described in Table 1.

| | Anti-IL-5 | | Placebo | | Odds Ratio | | | Odds Ratio |
|---|-------------------------|-----------|-------------|------------------------|------------|---------------------|------|---------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl |
| 1.2.1 Benralizumab | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | |
| Castro 2014 | 0 | 385 | 0 | 221 | | Not estimable | 2014 | |
| FitzGerald 2016 (CALIMA) | 26 | 866 | 7 | 440 | 29.3% | 1.91 [0.82, 4.45] | 2016 | |
| Park 2016 | 6 | 77 | 2 | 26 | 7.5% | 1.01 [0.19, 5.36] | 2016 | · · · · · · · · · · · · · · · · · · · |
| Bleecker 2016 (SIROCCO) | 40 | 797 | 14 | 407 | 54.1% | 1.48 [0.80, 2.76] | 2016 | |
| Nair 2017 (ZONDA) | 0 | 145 | 0 | 75 | | Not estimable | 2017 | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | |
| Panettieri 2020 (SOLANA) | 0 | 118 | 0 | 115 | | Not estimable | 2020 | |
| Harrison 2021 (ANDHI) | 0 | 427 | 0 | 229 | | Not estimable | 2021 | |
| Subtotal (95% CI) | | 2989 | | 1680 | 90.9% | 1.56 [0.97, 2.52] | | |
| Total events | 72 | | 23 | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi² = 0.51 | , df = 2 | P = 0.77 | 7); l ² = 0 |)% | | | |
| Test for overall effect: Z = 1.82 | 2 (P = 0.0) | 7) | | | | | | |
| | | | | | | | | |
| 1.2.2 Mepolizumab | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | |
| Bel 2014 (SIRIUS) | 0 | 69 | 0 | 66 | | Not estimable | 2014 | |
| Ortega 2014 (MENSA) | 0 | 385 | 0 | 191 | | Not estimable | 2014 | |
| Chupp 2017 (MUSCA) | - 0 | 273 | ñ | 278 | | Not estimable | 2017 | |
| Subtotal (95% CI) | - | 1228 | - | 735 | | Not estimable | | |
| Total events | 0 | | 0 | | | | | |
| Heterogeneity: Not applicable | Э | | | | | | | |
| Test for overall effect: Not app | - olicable | | | | | | | |
| | | | | | | | | |
| 1.2.3 Reslizumab | | | | | | | | |
| Castro 2011 | 0 | 53 | 0 | 53 | | Not estimable | 2011 | |
| Corren 2016 | 0 | 395 | 0 | 97 | | Not estimable | 2016 | |
| Bjermer 2016 | 4 | 206 | 3 | 105 | 9.1% | 0.67 [0.15, 3.07] | 2016 | • • • • |
| Bernstein 2020 (Study 1) | 0 | 237 | 0 | 231 | | Not estimable | 2020 | |
| Bernstein 2020 (Study 2) | 0 | 88 | 0 | 89 | | Not estimable | 2020 | |
| Subtotal (95% CI) | | 979 | | 575 | 9.1% | 0.67 [0.15, 3.07] | | |
| Total events | 4 | | 3 | | | | | |
| Heterogeneity: Not applicable | Э | | | | | | | |
| Test for overall effect: Z = 0.5 | 1 (P = 0.6 | 1) | | | | | | |
| | | | | | | | | |
| Total (95% CI) | | 5196 | | 2990 | 100.0% | 1.45 [0.92, 2.28] | | |
| Total events | 76 | | 26 | | | | | |
| Heterogeneity: Tau ² = 0.00; C | ¦hi² = 1.59 | l, df = 3 |) (P = 0.66 | 6); I ^z = (|)% | | | |
| Test for overall effect: Z = 1.5 | 8 (P = 0.1) | 1) | | | | | | Eavours Anti-II -5 Eavours Placebo |
| Test for subgroup differences | s: Chi ² = 1 | .07, df | = 1 (P = 0 | 0.30), I ^z | = 7.0% | | | |



3.2. Upper respiratory tract infections

From included RCTs, we managed to extract data on the following upper respiratory tract infections: nasopharyngitis, pharyngitis, upper respiratory tract infection (URTI), sinusitis, acute sinusitis, and rhinitis. *Anti*-IL-5 treatment resulted in non-significantly reduced odds of nasopharyngitis (OR = 0.90; 95 % CI from 0.76 to 1.07), compared to placebo. In terms of effect size, among the three treatments, mepolizumab showed the lowest odds for nasopharyngitis (OR = 0.75; 95 % CI from 0.56 to 1.01), followed by reslizumab (OR = 0.89; 95 % CI from 0.62 to 1.28), and benralizumab (OR = 0.97; 95 % CI from 0.75 to 1.26), all non-significantly different compared to placebo (Fig. 2). *Anti*-IL-5 treatment resulted in non-significantly increased odds of pharyngitis (OR = 1.45; 95 % CI from 0.92 to 2.28). Pharyngitis was not reported by patients included in RCTs on mepolizumab (OR = not estimable), while benralizumab and reslizumab resulted in non-significantly increased (OR = 1.56; 95 % CI from 0.97 to 2.52) and decreased (OR = 0.67; 95 % CI from 0.15 to 3.07) odds for pharyngitis, respectively (Fig. 3). We found non-significant differences between *anti*-IL-5 treatment and placebo for the reporting of URTI (OR = 0.97; 95 % CI from 0.82 to 1.15). For the same outcome, we observed similar results in the subgroup analysis for benralizumab (OR = 0.97; 95 % CI from 0.76 to 1.24), mepolizumab.

(OR = 0.87; 95 % CI from 0.59 to 1.30), and reslizumab (OR = 0.95; 95 % CI from 0.64 to 1.42) (Fig. 4). *Anti*-IL-5 treatment significantly reduced the odds for sinusitis (OR = 0.77; 95 % CI from 0.63 to 0.94), compared to placebo. In terms of effect size, albeit not reaching statistical significance, benralizumab showed the highest odds for sinusitis (OR = 0.75; 95 % CI from 0.53 to 1.06), followed by reslizumab (OR = 0.77; 95 % CI from 0.63 to 0.94) and mepolizumab (OR = 0.87; 95 % CI from 0.55 to 1.38) (Fig. 5). Similar results were observed for acute sinusitis (Fig. 6). *Anti*-IL-5 treatment resulted in no significant difference from placebo for the reporting of rhinitis (OR = 1.01; 95 % CI from 0.71 to 1.44). For the same outcome, benralizumab resulted in non-significant reduction

| | Anti-IL-5 | | Placebo | | Odds Ratio | | Odds Ratio | | | | | |
|---|--|-----------------|-----------|----------------------|------------|---------------------|------------|---|--|--|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | | | |
| 1.3.1 Benralizumab | | | | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | | | | |
| Castro 2014 | 30 | 385 | 14 | 221 | 6.8% | 1.25 [0.65, 2.41] | 2014 | , | | | | |
| Bleecker 2016 (SIROCCO) | 76 | 797 | 36 | 407 | 16.9% | 1.09 [0.72, 1.65] | 2016 | | | | | |
| FitzGerald 2016 (CALIMA) | 65 | 866 | 41 | 440 | 17.5% | 0.79 [0.52, 1.19] | 2016 | | | | | |
| Park 2016 | 21 | 77 | 8 | 26 | 3.1% | 0.84 [0.32, 2.23] | 2016 | | | | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | | | | |
| Nair 2017 (ZONDA) | 9 | 145 | 5 | 75 | 2.3% | 0.93 [0.30, 2.87] | 2017 | | | | | |
| Zeitlin 2018 (ALIZE) | 3 | 51 | 1 | 52 | 0.6% | 3.19 [0.32, 31.70] | 2018 | | | | | |
| Panettieri 2020 (SOLANA) | 6 | 118 | 6 | 115 | 2.2% | 0.97 [0.30, 3.11] | 2020 | | | | | |
| Harrison 2021 (ANDHI) | 0 | 427 | 0 | 229 | | Not estimable | 2021 | | | | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 49.2% | 0.97 [0.76, 1.24] | | • | | | | |
| Total events | 210 | | 111 | | | | | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 2.94, df = 6 (P = 0.82); I ² = 0% | | | | | | | | | | | | |
| Test for overall effect: Z = 0.2: | Test for overall effect: $Z = 0.22$ (P = 0.83) | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 1.3.2 Mepolizumab | | | | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | | | | |
| Haldar 2009 | 1 | 29 | 4 | 32 | 0.6% | 0.25 [0.03, 2.38] | 2009 | · | | | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | | | | |
| Ortega 2014 (MENSA) | 46 | 385 | 27 | 191 | 11.2% | 0.82 [0.49, 1.37] | 2014 | | | | | |
| Bel 2014 (SIRIUS) | 3 | 69 | 5 | 66 | 1.3% | 0.55 [0.13, 2.42] | 2014 | • | | | | |
| Chupp 2017 (MUSCA) | 17 | 273 | 14 | 278 | 5.5% | 1.25 [0.60, 2.59] | 2017 | | | | | |
| Subtotal (95% CI) | | 1228 | | 735 | 18.6% | 0.87 [0.59, 1.30] | | - | | | | |
| Total events | 67 | | 50 | | | | | | | | | |
| Heterogeneity: Tau² = 0.00; C | ≿hi² = 2.54 | , df = 3 | (P = 0.4) | $(7); ^2 = ($ | 3% | | | | | | | |
| Test for overall effect: Z = 0.6 | 7 (P = 0.5) | 0) | | | | | | | | | | |
| 133 Doelizumah | | | | | | | | | | | | |
| Castra 2014 | 2 | 60 | ~ | 60 | 4.000 | 0.00/0.07.0.001 | 2044 | | | | | |
| Castro 2011 Castro 2015 (Otudu 1) | 2 | 245 | 2 | 242 | 1.0% | 0.38 [0.07, 2.03] | 2011 | • | | | | |
| Castro 2015 (Study 1) | 39 | 245 | 32 | 243 | 11.4% | 1.25 [0.75, 2.07] | 2015 | | | | | |
| Castro 2015 (Study 2) | 0 | 232 | 10 | 232 | 3.970 | 0.48 [0.20, 1.10] | 2015 | | | | | |
| Bjermer 2016 | 8 | 205 | 3 | 105 | 1.0% | 1.37 [0.36, 5.29] | 2010 | | | | | |
| Corren 2016 Demetein 2020 (Otudu 2) | 42 | 395 | | 97 | 0.9% | | 2010 | | | | | |
| Bernstein 2020 (Study 2) | 20 | 88 | 5 | 224 | 0.0% | | 2020 | | | | | |
| Subtotal (95% CI) | 28 | 1456 | 19 | 231 | 7.8% | 1.49 [0.81, 2.76] | 2020 | | | | | |
| Tatal aventa | 400 | 1450 | 04 | 1050 | JZ.270 | 0.95 [0.04, 1.42] | | | | | | |
| I otal events | 128 | 16 0 | 91 | | 2000 | | | | | | | |
| Toot for everall effect: 7 = 0.2 | /IIIT = 8.84 4 /D = 0.01 | i, ui = b 1∖ | (r= 0.1) | o), in = . | 5270 | | | | | | | |
| Test for overall effect. $Z = 0.2$ | 4 (⊢≐ 0.8) | 0 | | | | | | | | | | |
| Total (95% CI) | | 5673 | | 3465 | 100.0% | 0.97 [0.82, 1.15] | | + | | | | |
| Total events | 405 | | 252 | | | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 14.7 | '2, df = | 17 (P = 0 | .62); I ^z | = 0% | | | | | | | |
| Test for overall effect: Z = 0.3 | 4 (P = 0.7) | 3) | | | | | | U.Z U.O I Z D Eavours Anti-II -5 Eavours Placebo | | | | |
| Test for subgroup differences: Chi ² = 0.21, df = 2 (P = 0.90), I ² = 0% | | | | | | | | | | | | |

Fig. 4. Upper respiratory tract infection.

| | Anti-IL-5 Placebo | | | bo | Odds Ratio | | | Odds Ratio | | | |
|--|------------------------|------------------|------------|-------------------|------------|---------------------|------|---|--|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | | |
| 1.4.1 Benralizumab | | | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | | | |
| Castro 2014 | 24 | 385 | 10 | 221 | 7.0% | 1.40 [0.66, 2.99] | 2014 | | | | |
| FitzGerald 2016 (CALIMA) | 41 | 866 | 37 | 440 | 19.0% | 0.54 [0.34, 0.86] | 2016 | | | | |
| Park 2016 | 5 | 77 | 3 | 26 | 1.8% | 0.53 [0.12, 2.40] | 2016 | • | | | |
| Bleecker 2016 (SIROCCO) | 39 | 797 | 28 | 407 | 16.0% | 0.70 [0.42, 1.15] | 2016 | | | | |
| Nair 2017 (ZONDA) | 9 | 145 | 8 | 75 | 4.0% | 0.55 [0.20, 1.50] | 2017 | | | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | | | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | | | | |
| Panettieri 2020 (SOLANA) | 1 | 118 | 4 | 115 | 0.8% | 0.24 [0.03, 2.15] | 2020 | + | | | |
| Harrison 2021 (ANDHI) | 28 | 427 | 12 | 229 | 8.3% | 1.27 [0.63, 2.55] | 2021 | | | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 56.9% | 0.75 [0.53, 1.06] | | | | | |
| Total events | 147 | | 102 | | | | | | | | |
| Heterogeneity: Tau ² = 0.06; Chi ² = 8.41, df = 6 (P = 0.21); l ² = 29% | | | | | | | | | | | |
| Test for overall effect: Z = 1.64 | 4 (P = 0.1) | 0) | | | | | | | | | |
| 1.4.2 Mepolizumab | | | | | | | | | | | |
| Flood-Page 2003 | Π | 11 | n | 13 | | Not estimable | 2003 | | | | |
| Haldar 2009 | 0 | 29 | ň | 32 | | Not estimable | 2000 | | | | |
| Payord 2012 (DREAM) | 0 | 461 | ů n | 155 | | Not estimable | 2000 | | | | |
| Rel 2014 (SIRIUS) | 7 | 69 | 0 | 66 | 3.1% | 1 1 3 10 36 3 551 | 2012 | | | | |
| Ortego 2014 (MENSA) | 20 | 295 | 10 | 101 | 10.6% | 0.79 [0.30, 3.35] | 2014 | | | | |
| Chunn 2017 (MUSCA) | 23 | 273 | 12 | 278 | 5 7% | 0.70 [0.42, 1.45] | 2014 | | | | |
| Subtotal (95% Cl) | 11 | 1228 | 12 | 735 | 19.4% | 0.87 [0.55, 1.38] | 2017 | | | | |
| Total events | 47 | | 36 | | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 0.34 | , df = 2 | (P = 0.86 | $5); I^2 = 0$ |)% | | | | | | |
| Test for overall effect: Z = 0.59 | 9 (P = 0.5 | 6) | | | | | | | | | |
| 1.4.3 Reslizumab | | | | | | | | | | | |
| Castro 2011 | 2 | 53 | 2 | 53 | 1.0% | 1 00 0 14 7 371 | 2011 | · · · · · · · · · · · · · · · · · · · | | | |
| Castro 2015 (Study 1) | 21 | 245 | 29 | 243 | 11.5% | 0.69 [0.38, 1.25] | 2015 | | | | |
| Castro 2015 (Study 7) | 2 q | 232 | 10 | 232 | 4.7% | 0.90 [0.36, 7.25] | 2015 | | | | |
| Corren 2016 | 22 | 395 | 7 | 97 | 5.2% | 0.76 [0.31 1.83] | 2016 | | | | |
| Biermer 2016 | 1 | 206 | 2 | 105 | 1 / 96 | | 2010 | · · · · · · · · · · · · · · · · · · · | | | |
| Bernstein 2020 (Study 1) | , 0 | 237 | ñ | 231 | 1.470 | Not estimable | 2020 | | | | |
| Bernstein 2020 (Study 7) | 0 | 88 | ñ | 201 | | Not estimable | 2020 | | | | |
| Subtotal (95% CI) | | 1456 | | 1050 | 23.7% | 0.77 [0.51, 1.16] | 2020 | | | | |
| Total events | 58 | | 50 | | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ^z = 0.40 |), df = 4 | (P = 0.98) | 8); I2 = 0 |)% | | | | | | |
| Test for overall effect: Z = 1.23 | 3 (P = 0.2) | 2) | | | | | | | | | |
| Total (95% CI) | | 5673 | | 3465 | 100.0% | 0.77 [0.63, 0.94] | | • | | | |
| Total events | 252 | | 188 | | | | | ÷ | | | |
| Heterogeneity: $Tau^2 = 0.00$: C | -202 hi²=9.57 | ' df = 1 | 4(P = 0.7) | 79): IZ = | 0% | | | | | | |
| Test for overall effect: 7 = 2.60 | 1 (P = 0.0) | , <u>a</u> , _ , | | <i>-</i> // - | 0.70 | | | 0.2 0.5 1 2 5 | | | |
| Test for subgroup differences | s: Chi² = □ | / 128 df | = 2 (P = 0 | 1 871 IZ | = 0% | | | Favours Anti-IL-5 Favours Placebo | | | |
| estion subgroup unierences. Chr= 0.28, ur= 2 (F= 0.87), F= 0% | | | | | | | | | | | |

Fig. 5. Sinusitis.

of rhinitis reporting (OR = 0.90; 95 % CI from 0.61 to 1.33), mepolizumab in non-significant increased (OR = 1.85; 95 % CI from 0.72 to 4.78) odds, while no rhinitis events were reported for reslizumab (OR = not estimable) (Fig. 7).

3.3. Lower respiratory tract infections and influenza

From included RCTs, we managed to extract data on the following lower respiratory tract infections: bronchitis, pneumonia, and influenza. *Anti*-IL-5 treatment was associated with a significant reduction of bronchitis (OR = 0.71; 95 % CI from 0.59 to 0.86). Similar results were obtained in the subgroup analysis, with, in order of effect size from the lower to higher, a significant reduction in the odds for benralizumab (OR = 0.76; 95 % CI from 0.60 to 0.96), a non-significant reduction in the odds of mepolizumab (OR = 0.69; 95 % CI from 0.40 to 1.20), and a significant reduction in the odds of reslizumab (OR = 0.60; 95 % CI from 0.40 to 0.90), compared to placebo (Fig. 8). Conversely, *anti*-IL-5 treatment resulted in non-significant reduction of pneumonia (OR = 0.56; 95 % CI from 0.10 to 2.01). In terms of effect size, among the three treatments, mepolizumab showed the lowest odds for pneumonia (OR = 0.20; 95 % CI from 0.27 to 2.36), all non-significantly different from placebo (Fig. 9). *Anti*-IL-5 treatment resulted in non-significantly reduced odds for influenza (OR = 0.84; 95 % CI from 0.65 to 1.09). Influenza was not reported by patients included in RCTs on mepolizumab (OR = not estimable), while benralizumab (OR = 0.81; 95 % CI from 0.59 to 1.11) and reslizumab (OR = 0.92; 95 % CI from 0.59 to 1.43) resulted in non-significantly reduced odds for influenza, respectively (Fig. 10).

| | Anti-IL-5 | | Placebo | | Odds Ratio | | | Odds Ratio | | |
|--|------------------------|-------------------|------------|------------------------|------------------------|---|------|---|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | |
| 1.5.1 Benralizumab | | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | | |
| Bleecker 2016 (SIROCCO) | 23 | 797 | 10 | 407 | 31.5% | 1.18 [0.56, 2.50] | 2016 | | | |
| FitzGerald 2016 (CALIMA) | 11 | 866 | 14 | 440 | 29.2% | 0.39 [0.18, 0.87] | 2016 | < | | |
| Park 2016 | 0 | 77 | 0 | 26 | | Not estimable | 2016 | | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | | |
| Nair 2017 (ZONDA) | 0 | 145 | 0 | 75 | | Not estimable | 2017 | | | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | | | |
| Panettieri 2020 (SOLANA) | 0 | 118 | 0 | 115 | | Not estimable | 2020 | | | |
| Harrison 2021 (ANDHI) | 0 | 427 | 0 | 229 | | Not estimable | 2021 | | | |
| Subtotal (95% CI) | | 2604 | | 1459 | 60.7% | 0.69 [0.23, 2.02] | | | | |
| Total events | 34 | | 24 | | | | | | | |
| Heterogeneity: Tau ² = 0.45; Chi ² = 3.89, df = 1 (P = 0.05); l ² = 74% | | | | | | | | | | |
| Test for overall effect: Z = 0.68 | 8 (P = 0.49 | 3) | | | | | | | | |
| 1.5.2 Mepolizumab | | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | | |
| Ortega 2014 (MENSA) | 0 | 385 | 0 | 191 | | Not estimable | 2014 | | | |
| Bel 2014 (SIRIUS) | 0 | 69 | 0 | 66 | | Not estimable | 2014 | | | |
| Chupp 2017 (MUSCA) | 0 | 273 | 0 | 278 | | Not estimable | 2017 | | | |
| Subtotal (95% CI) | | 1228 | | 735 | | Not estimable | | | | |
| Total events | 0 | | 0 | | | | | | | |
| Heterogeneity: Not applicable | 9 | | | | | | | | | |
| Test for overall effect: Not app | olicable | | | | | | | | | |
| 1.5.3 Reslizumab | | | | | | | | | | |
| Castro 2011 | 0 | 53 | 0 | 53 | | Not estimable | 2011 | | | |
| Bjermer 2016 | 0 | 206 | 0 | 105 | | Not estimable | 2016 | | | |
| Corren 2016 | 0 | 395 | 0 | 97 | | Not estimable | 2016 | | | |
| Bernstein 2020 (Study 2) | 2 | 88 | 3 | 89 | 7.7% | 0.67 [0.11, 4.09] | 2020 | • • • | | |
| Bernstein 2020 (Study 1) Subtotal (95% CI) | 14 | 237 979 | 15 | 231 575 | 31.6% 39.3 % | 0.90 [0.43, 1.92] 0.86 [0.43, 1.73] | 2020 | | | |
| Total events | 16 | | 18 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ^z = 0.09 | , df = 1 | (P = 0.76) | $5); I^{2} = 0$ |)% | | | | | |
| Test for overall effect: Z = 0.41 | (P = 0.6 | 3) | • | | | | | | | |
| Total (95% CI) | | 4811 | | 2769 | 100.0% | 0.75 [0.44, 1.27] | | | | |
| Total events | 50 | | 42 | | | | | | | |
| Heterogeneity: Tau ² = 0.08; C | hi ² = 4.19 | , df = 3 | (P = 0.24) | 4); l ² = 2 | 8% | | | | | |
| Test for overall effect: Z = 1.08 | 6 (P = 0.2 | 3) | | | | | | U.Z U.S 1 Z 5 Eavoure Antill 5 Eavoure Placeba | | |
| Fest for subgroup differences: Chi ² = 0.13, df = 1 (P = 0.72), l ² = 0% | | | | | | | | | | |



3.4. ED or hospital admission

In included studies, ED or hospital admission was reported as an outcome related to asthma exacerbation. On the contrary, ED or hospital admission for infection was not reported. Neither was it possible to extract data on whether an infection was present at the time of ED or hospital admission due to asthma exacerbation. This outcome was reported by 12 included RCTs [16–19,23,25,26,28–30, 33]. *Anti*-IL-5 antibodies were associated to reduced odds of ED or hospital admission for asthma exacerbation (OR = 0.59; 95 % CI from 0.40 to 0.88). In terms of effect sizes, benralizumab showed the lowest odds for ED or hospital admission due to asthma exacerbation (OR = 0.47; 95 % CI from 0.20 to 1.12), followed by mepolizumab (OR = 0.53; 95 % CI from 0.20 to 1.42) and reslizumab (OR = 0.74; 95 % CI from 0.47 to 1.17), all statistically non-significant (Fig. 11).

4. Discussion

We conducted a systematic review and a meta-analysis to explore the association of *anti*-IL-5 antibodies administration with the reporting of infective events in patients with asthma. From our analysis emerged a significant reduction in the reporting of sinusitis and bronchitis and a reduction in the odds for ED or hospital admission due to asthma exacerbation for overall *anti*-IL-5 antibodies compared to placebo. These observations are likely correlated to the mechanism of action of *anti*-IL-5 antibodies and reflect their clinical efficacy on eosinophilic inflammation. Indeed, *anti*-IL-5s are currently being evaluated also for chronic rhinosinusitis and nasal polyposis [34–36]. These conditions share physio-pathological mechanisms with asthma and are frequently reported in patients with asthma. Thus, the significant reduction of sinusitis observed in our study with *anti*-IL-5 antibodies may be related to the concurrent

| | Anti-IL-5 Placebo | | bo | | Odds Ratio | | Odds Ratio | | |
|---|-------------------------|----------|------------|----------------|------------|---------------------|------------|---------------------------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | |
| 1.6.1 Benralizumab | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | |
| Castro 2014 | 11 | 385 | 8 | 221 | 14.8% | 0.78 [0.31, 1.98] | 2014 | • • • • • • • • • • • • • • • • • • • | |
| Bleecker 2016 (SIROCCO) | 26 | 797 | 15 | 407 | 30.3% | 0.88 [0.46, 1.68] | 2016 | | |
| FitzGerald 2016 (CALIMA) | 29 | 866 | 17 | 440 | 34.0% | 0.86 [0.47, 1.59] | 2016 | | |
| Park 2016 | 0 | 77 | 0 | 26 | | Not estimable | 2016 | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | |
| Nair 2017 (ZONDA) | 8 | 145 | 2 | 75 | 5.1% | 2.13 [0.44, 10.30] | 2017 | | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | | |
| Panettieri 2020 (SOLANA) | 0 | 118 | 0 | 115 | | Not estimable | 2020 | | |
| Harrison 2021 (ANDHI) | 0 | 427 | 0 | 229 | | Not estimable | 2021 | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 84.2% | 0.90 [0.61, 1.33] | | - | |
| Total events | 74 | | 42 | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ^z = 1.26 | , df = 3 | (P = 0.74) | $(1); I^2 = 0$ |)% | | | | |
| Test for overall effect: Z = 0.52 | 2 (P = 0.6) | J) | | | | | | | |
| | | | | | | | | | |
| 1.6.2 Mepolizumab | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | |
| Ortega 2014 (MENSA) | 0 | 385 | 0 | 191 | | Not estimable | 2014 | | |
| Bel 2014 (SIRIUS) | 5 | 69 | 1 | 66 | 2.7% | 5.08 [0.58, 44.68] | 2014 | | |
| Chupp 2017 (MUSCA) | 10 | 273 | 7 | 278 | 13.2% | 1.47 [0.55, 3.92] | 2017 | | |
| Subtotal (95% CI) | | 1228 | | 735 | 15.8% | 1.85 [0.72, 4.78] | | | |
| Total events | 15 | | 8 | | | | | | |
| Heterogeneity: Tau ² = 0.04; C | hi² = 1.05 | , df = 1 | (P = 0.31) | $); ^2 = 6$ | 5% | | | | |
| Test for overall effect: Z = 1.27 | ' (P = 0.2) | D) | | | | | | | |
| | | | | | | | | | |
| 1.6.3 Reslizumab | | | | | | | | | |
| Castro 2011 | 0 | 53 | 0 | 53 | | Not estimable | 2011 | | |
| Castro 2015 (Study 1) | 0 | 245 | 0 | 243 | | Not estimable | 2015 | | |
| Castro 2015 (Study 2) | 0 | 232 | 0 | 232 | | Not estimable | 2015 | | |
| Bjermer 2016 | 0 | 206 | 0 | 105 | | Not estimable | 2016 | | |
| Corren 2016 | 0 | 395 | 0 | 97 | | Not estimable | 2016 | | |
| Bernstein 2020 (Study 2) | 0 | 88 | 0 | 89 | | Not estimable | 2020 | | |
| Bernstein 2020 (Study 1) | 0 | 237 | 0 | 231 | | Not estimable | 2020 | | |
| Subtotal (95% CI) | | 1456 | | 1050 | | Not estimable | | | |
| Total events | 0 | | 0 | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | | |
| Test for overall effect: Not app | licable | | | | | | | | |
| | | 5070 | | 0.105 | 100.00 | 10110 74 110 | | | |
| l otal (95% CI) | No.232 - 4444 | 5673 | | 3465 | 100.0% | 1.01 [0.71, 1.44] | | - | |
| Total events | 89 | | 50 | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 4.30 | , df = 5 | (P = 0.51 |); l² = (| 1% | | | 0.2 0.5 1 2 5 | |
| Test for overall effect: Z = 0.05 | 5 (P = 0.9) | 5) | | | | | | Favours Anti-IL-5 Favours Placebo | |
| l est for subgroup differences | :: Chi ² = 1 | .88, df | = 1 (P = (| J.17), I² | = 46.9% | | | | |

Fig. 7. Rhinitis.

reduced inflammation of the nasal mucosa while the reduction of bronchitis likely reflects an improvement in the bronchial system's status.

The reporting of other included infection events (nasopharyngitis, pharyngitis, URTI, acute sinusitis, rhinitis, pneumonia, and influenza) was non-significantly different. However, we observed differences both in directions and magnitudes of some effect sizes. In particular, benralizumab was associated with increased odds of pharyngitis, although at limits of statistical non-significance; a similar trend was observed also for mepolizumab on the reporting of rhinitis. Similar to bronchitis, *anti*-IL-5 treatment was associated with a non-significant reduction in the odds for pneumonia. However, for both infections and more importantly pneumonia the ORs of benralizumab were closer to the line of non-significance compared to those of reslizumab and mepolizumab in terms of effect size, (i.e., benralizumab reduced less the occurrence of bronchitis and especially pneumonia). This trend, albeit limited by the sample size and the low number of reported patients with the event, was similar to that observed in the aforementioned prospective cohort study [12].

Anti-IL-5 treatment was associated with a significant reduction of ED or hospital admission for asthma exacerbation. In terms of effect sizes, the greatest reduction in ED or hospital admission was observed with benralizumab, followed by mepolizumab and reslizumab. This reduction was non-significant in all the three drug subgroups; however, this could be explained by the relatively low frequency of the observed outcome, leading to large confidence intervals. Of note, the cumulative effect sizes and their directions were consistent across the three cumulative subgroups. In this context, the comparison of the trend of the clinical efficacy (i.e., the reduction of ED or hospital admission for exacerbation) and the trend of the reporting of some infection events is conflicting. In terms of effect size and direction, on one side, drugs such as benralizumab and mepolizumab reduced exacerbations and *anti*-IL-5 treatment reduced

| | Anti-IL-5 | | Placebo | | | Odds Ratio | | Odds Ratio | | |
|---|-------------------------|-----------|----------------------|------------------------|----------------|---------------------|------|---|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | |
| 1.7.1 Benralizumab | | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | | |
| Castro 2014 | 25 | 385 | 16 | 221 | 8.2% | 0.89 [0.46, 1.71] | 2014 | | | |
| FitzGerald 2016 (CALIMA) | 84 | 866 | 52 | 440 | 25.7% | 0.80 [0.56, 1.16] | 2016 | | | |
| Park 2016 | 7 | 77 | 2 | 26 | 1.3% | 1.20 [0.23, 6.18] | 2016 | | | |
| Bleecker 2016 (SIROCCO) | 43 | 797 | 30 | 407 | 14.9% | 0.72 [0.44, 1.16] | 2016 | | | |
| Nair 2017 (ZONDA) | 11 | 145 | 12 | 75 | 4.6% | 0.43 [0.18, 1.03] | 2017 | • • • | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | | | |
| Panettieri 2020 (SOLANA) | 6 | 118 | 3 | 115 | 1.7% | 2.00 [0.49, 8.20] | 2020 | | | |
| Harrison 2021 (ANDHI) | 22 | 427 | 18 | 229 | 8.3% | 0.64 [0.33, 1.21] | 2021 | | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 64.7% | 0.76 [0.60, 0.96] | | ◆ | | |
| Total events | 198 | | 133 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | ¢hi² = 4.39 | 9, df = 6 | i (P = 0.6) | 2); l ² = l | 3% | | | | | |
| Test for overall effect: Z = 2.3 | 3 (P = 0.0 | 2) | | | | | | | | |
| | | | | | | | | | | |
| 1.7.2 Mepolizumab | | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | | |
| Bel 2014 (SIRIUS) | 7 | 69 | 6 | 66 | 2.6% | 1.13 [0.36, 3.55] | 2014 | | | |
| Ortega 2014 (MENSA) | 23 | 385 | 18 | 191 | 8.4% | 0.61 [0.32, 1.16] | 2014 | | | |
| Chupp 2017 (MUSCA) | 0 | 273 | 1 | 278 | 0.3% | 0.34 [0.01, 8.34] | 2017 | · · · · · · · · · · · · · · · · · · · | | |
| Subtotal (95% CI) | | 1228 | | 735 | 11.3% | 0.69 [0.40, 1.20] | | | | |
| Total events | 30 | | 25 | | | | | | | |
| Heterogeneity: Tau² = 0.00; C | hi ² = 1.04 | l, df = 2 | (P = 0.6) | 0); I² = I | 3% | | | | | |
| Test for overall effect: Z = 1.3 | 1 (P = 0.1 | 9) | | | | | | | | |
| 173 Reslizumah | | | | | | | | | | |
| Costro 2011 | 2 | 50 | 2 | 50 | 1.00 | 0.65 (0.1.0, 4.00) | 2011 | • · · · · · · · · · · · · · · · · · · · | | |
| Castro 2011 Costro 2015 (Study 1) | 10 | 246 | د ۲۸ | 242 | 7.10% | 0.00 [0.10, 4.00] | 2011 | · | | |
| Castro 2015 (Study 1) | 13 | 240 | 24 | 243 | 1 0 00 | 0.01 [0.20, 1.00] | 2015 | | | |
| Castro 2015 (Study 2) | | 202 | 14 | 232 | 1.070 | 0.14 [0.03, 0.00] | 2010 | | | |
| Diarmar 2016 | 14 | 390 | 5 | 37 | 3.070 | 0.00 [0.21, 1.48] | 2010 | | | |
| Djermer 2010 Bornotoin 2020 (Ptudu 1) | 10 | 200 | 17 | 200 | 2.J70 6.D00 | 0.70 [0.22, 2.27] | 2010 | | | |
| Pornetoin 2020 (Study 1) | 13 | 237 | | 231 | 2.2.70 | 1.65 (0.42, 6.74) | 2020 | | | |
| Subtotal (95% Cl) | 0 | 1456 | 4 | 1050 | 2.0% | 0.60 [0.40, 0.90] | 2020 | | | |
| Total events | 67 | | 72 | | 2 | 0.00 [0.10, 0.00] | | | | |
| Heteroneneity: Tau ² – 0.02: 0 | 'hi≅−6.50 | df – R | (P = 0.3) | 7) - 12 - 3 | 296 | | | | | |
| Test for overall effect: Z = 2.5 | 0 (P = 0.02) | 1) | ν _μ = 0.5 | | | | | | | |
| Total (95% CI) | | 5673 | | 3465 | 100.0% | 0.71 [0.59, 0.86] | | • | | |
| Total events | 285 | | 231 | | | | | | | |
| Heterogeneity: $Tau^2 = 0.00^{\circ}$ C | ; hi² = 13.0 |)0. df= | 16(P = 0 | l.67): I ₹ | = 0% | | | | | |
| Test for overall effect: Z = 3.6 | 1 (P = 0.0) | 003) | | | * | | | 0.2 0.5 1 2 5 Foreign Antilli 5 Foreign Plants | | |
| Test for subgroup differences | s: Chi ² = 1 | .03. df | = 2 (P = 1 | 0.60). P | ²= 0% | | | Favours Anti-IL-5 Favours Placebo | | |
| | | | | | - ··· | | | | | |

Fig. 8. Bronchitis.

| | Anti-IL | -5 | Placebo Odds Ratio | | | Odds Ratio | Ratio Odds Ratio | | | |
|--|------------------------|----------|--------------------|------------------------|----------------|---------------------|------------------|---|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | |
| 1.8.1 Benralizumab | | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | | |
| Castro 2014 | 5 | 385 | 1 | 221 | 14.4% | 2.89 [0.34, 24.94] | 2014 | | | |
| Bleecker 2016 (SIROCCO) | 0 | 797 | 0 | 407 | | Not estimable | 2016 | | | |
| FitzGerald 2016 (CALIMA) | 0 | 866 | 0 | 440 | | Not estimable | 2016 | | | |
| Park 2016 | 0 | 77 | 0 | 26 | | Not estimable | 2016 | | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | | |
| Nair 2017 (ZONDA) | 3 | 145 | 3 | 75 | 25.2% | 0.51 [0.10, 2.58] | 2017 | • • | | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | | | |
| Panettieri 2020 (SOLANA) | 0 | 118 | 0 | 115 | | Not estimable | 2020 | | | |
| Harrison 2021 (ANDHI) | 2 | 427 | 2 | 229 | 17.2% | 0.53 [0.07, 3.82] | 2021 | • • • · · · · · · · · · · · · · · · · · | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 56.8% | 0.80 [0.27, 2.36] | | | | |
| Total events | 10 | | 6 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 1.88 | , df = 2 | (P = 0.3) | 3); l ² = 0 | 1% | | | | | |
| Test for overall effect: Z = 0.40 (P = 0.69) | | | | | | | | | | |
| | | | | | | | | | | |
| 1.8.2 Mepolizumab | | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | | |
| Ortega 2014 (MENSA) | 0 | 385 | 0 | 191 | | Not estimable | 2014 | | | |
| Bel 2014 (SIRIUS) | 0 | 69 | 3 | 66 | 7.5% | 0.13 [0.01, 2.58] | 2014 | • | | |
| Chupp 2017 (MUSCA) | 0 | 273 | 1 | 278 | 6.5% | 0.34 [0.01, 8.34] | 2017 | · · · · · · · · · · · · · · · · · · · | | |
| Subtotal (95% CI) | | 1228 | | 735 | 14.0% | 0.20 [0.02, 1.80] | | | | |
| Total events | 0 | | 4 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 0.18 | , df = 1 | (P = 0.6) | 7); l ² = 0 |)% | | | | | |
| Test for overall effect: Z = 1.43 | 3 (P = 0.19 | 5) | | | | | | | | |
| | | | | | | | | | | |
| 1.8.3 Reslizumab | | | | | | | | | | |
| Castro 2011 | 0 | 53 | 0 | 53 | | Not estimable | 2011 | | | |
| Castro 2015 (Study 1) | 0 | 245 | 0 | 243 | | Not estimable | 2015 | | | |
| Castro 2015 (Study 2) | 0 | 232 | 0 | 232 | | Not estimable | 2015 | | | |
| Bjermer 2016 | 0 | 206 | 0 | 105 | | Not estimable | 2016 | | | |
| Corren 2016 | 0 | 395 | 0 | 97 | | Not estimable | 2016 | | | |
| Bernstein 2020 (Study 1) | 2 | 237 | 4 | 231 | 22.8% | 0.48 [0.09, 2.66] | 2020 | • • | | |
| Bernstein 2020 (Study 2) | 0 | 88 | 1 | 89 | 6.4% | 0.33 [0.01, 8.29] | 2020 | · · · · · · · · · · · · · · · · · · · | | |
| Subtotal (95% CI) | | 1456 | | 1050 | 29.3% | 0.45 [0.10, 2.01] | | | | |
| Total events | 2 | | 5 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi² = 0.04 | , df = 1 | (P = 0.8) | 4); I ² = 0 |)% | | | | | |
| Test for overall effect: Z = 1.05 | 5 (P = 0.2 | 3) | | | | | | | | |
| Total (95% CI) | | 5673 | | 3465 | 100.0 % | 0.56 [0.25, 1.26] | | | | |
| Total events | 12 | | 15 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi² = 3.39 | , df = 6 | i (P = 0.7) | 6); I ² = 0 |)% | | | | | |
| Test for overall effect: Z = 1.41 | 1 (P = 0.1) | 3) | | | | | | Eavours Anti-II -5 Eavours Placebo | | |
| Test for subgroup differences | s: Chi² = 1 | .34, df | = 2 (P = I | 0.51), I ^z | = 0% | | | . arears and the of the other the own | | |



sinusitis and bronchitis; on the other hand, benralizumab was less effective in reducing pneumonia and even seemed to increase pharyngitis. Also, we were not able to evaluate ED or hospital admission for infections and neither to discriminate if the cases of exacerbation leading to ED or hospital admission were pure asthmatic re-accruals or were associated with infections, neutrophilia, or other signs of infection.

Altogether, our findings led us to speculate whether benralizumab might increase the risk of some infections in asthmatic patients due to its mechanism of action which targets IL-5 receptors instead of circulating IL-5 such as mepolizumab and reslizumab. While benralizumab inhibits the binding of IL-5 to its receptor and induces antibody-dependent cell cytotoxicity on IL-5R + cells [1], mepolizumab action could be exerted through reducing the mobilization of eosinophils from bone marrow, reducing the maturation of eosinophils from progenitors, having a different selectivity on different subset of eosinophils, and/or a return of eosinophils to peripheral blood from the tissues [37].

4.1. Study limitations

Our study presents some limitations and caveats. Events presented in RCTs are generally presented as "patient with event" over the total number of patients and are divided by different event categories. However, the same patient could be included in multiple, also similar, events. For this reason, we could not cumulate all respiratory tract infection events to avoid the possible artefactual duplication of included patients even when some events were similar in the classification (e.g., nasopharyngitis, pharyngitis, sinusitis, acute

| | Anti-IL-5 Placebo | | | bo | Odds Ratio | | | Odds Ratio | | |
|---|------------------------|----------|--------------------|------------------------|------------|---------------------|------|--|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | | |
| 1.9.1 Benralizumab | | | | | | | | | | |
| Laviolette 2013 | 0 | 17 | 0 | 10 | | Not estimable | 2013 | | | |
| Castro 2014 | 23 | 385 | 14 | 221 | 14.1% | 0.94 [0.47, 1.87] | 2014 | | | |
| FitzGerald 2016 (CALIMA) | 36 | 866 | 24 | 440 | 23.6% | 0.75 [0.44, 1.28] | 2016 | | | |
| Park 2016 | 11 | 77 | 1 | 26 | 1.5% | 4.17 [0.51, 33.97] | 2016 | | | |
| Bleecker 2016 (SIROCCO) | 36 | 797 | 23 | 407 | 23.0% | 0.79 [0.46, 1.35] | 2016 | | | |
| Nair 2017 (ZONDA) | 4 | 145 | 5 | 75 | 3.7% | 0.40 [0.10, 1.53] | 2017 | • • • • • • • • • • • • • • • • • • • | | |
| Ferguson 2017 (BISE) | 0 | 106 | 0 | 105 | | Not estimable | 2017 | | | |
| Zeitlin 2018 (ALIZE) | 0 | 51 | 0 | 52 | | Not estimable | 2018 | | | |
| Panettieri 2020 (SOLANA) | 0 | 118 | 0 | 115 | | Not estimable | 2020 | | | |
| Harrison 2021 (ANDHI) | 0 | 427 | 0 | 229 | | Not estimable | 2021 | | | |
| Subtotal (95% CI) | | 2989 | | 1680 | 65.8% | 0.81 [0.59, 1.11] | | - | | |
| Total events | 110 | | 67 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 3.71, df = 4 (P = 0.45); l ² = 0% | | | | | | | | | | |
| Test for overall effect: Z = 1.34 | 4 (P = 0.1) | 8) | | | | | | | | |
| | | | | | | | | | | |
| 1.9.2 Mepolizumab | | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | | |
| Haldar 2009 | 0 | 29 | 0 | 32 | | Not estimable | 2009 | | | |
| Pavord 2012 (DREAM) | 0 | 461 | 0 | 155 | | Not estimable | 2012 | | | |
| Bel 2014 (SIRIUS) | 0 | 69 | 0 | 66 | | Not estimable | 2014 | | | |
| Chupp 2017 (MUSCA) | 0 | 273 | 0 | 278 | | Not estimable | 2017 | | | |
| Subtotal (95% CI) | | 843 | | 544 | | Not estimable | | | | |
| Total events | 0 | | 0 | | | | | | | |
| Heterogeneity: Not applicable | Э | | | | | | | | | |
| Test for overall effect: Not app | olicable | | | | | | | | | |
| | | | | | | | | | | |
| 1.9.3 Reslizumab | | | | | | | | | | |
| Castro 2011 | 0 | 53 | 0 | 53 | | Not estimable | 2011 | | | |
| Castro 2015 (Study 1) | 18 | 245 | 23 | 243 | 16.0% | 0.76 [0.40, 1.44] | 2015 | | | |
| Castro 2015 (Study 2) | 6 | 232 | 7 | 232 | 5.4% | 0.85 [0.28, 2.58] | 2015 | | | |
| Corren 2016 | 8 | 395 | 3 | 97 | 3.7% | 0.65 [0.17, 2.49] | 2016 | • • • | | |
| Bjermer 2016 | 0 | 206 | 0 | 105 | | Not estimable | 2016 | | | |
| Bernstein 2020 (Study 1) | 10 | 237 | 7 | 231 | 6.9% | 1.41 [0.53, 3.77] | 2020 | | | |
| Bernstein 2020 (Study 2) | 4 | 88 | 2 | 89 | 2.2% | 2.07 [0.37, 11.61] | 2020 | | | |
| Subtotal (95% CI) | | 1456 | | 1050 | 34.2% | 0.92 [0.59, 1.43] | | | | |
| Total events | 46 | | 42 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ^z = 2.20 | , df = 4 | (P = 0.7) | 0); I² = 0 |]% | | | | | |
| Test for overall effect: Z = 0.38 | B (P = 0.7 | 1) | | | | | | | | |
| Total (95% CI) | | 5288 | | 3274 | 100.0% | 0.84 [0.65, 1.09] | | - | | |
| Total events | 156 | | 109 | | | | | | | |
| Heterogeneity: Tau ² = 0.00; C | hi ² = 6.13 | , df = 9 | P = 0.73 | 3); I ² = (|)% | | | | | |
| Test for overall effect: Z = 1.31 | 1 (P = 0.1) | 9) | and profits in the | | | | | U.Z U.S 1 Z 5 Eavoure Antill, 5 Eavoure Plaashe | | |
| rest for subgroup differences: Chi ² = 0.23, df = 1 (P = 0.63), i ² = 0% | | | | | | | | | | |



sinusitis). Also, as discussed before, we could not distinguish exacerbations associated with markers of eosinophilia (i.e., *anti*-IL-5 inefficacy) from exacerbations possibly associated to infections that may have elicited asthma worsening (i.e., a possible effect of *anti*-IL-5 in increasing the risk of some infections in a subset of individuals).

5. Conclusion

Our results suggest that *anti*-IL-5 treatments might have different effects on the reporting of some infection events in patients with asthma. The almost complete depletion of eosinophils by benralizumab might lead to an increased risk of some infections. However, the evidence is limited and these results are far from conclusive and strongly suggest the need of future studies to evaluate the risk of infections in patients with asthma receiving *anti*-IL-5 treatments.

Data availability statement

The data supporting the findings of this study are available within the article. No further data were used for the realization of this study.

| | Anti-IL | -5 | Placebo | | Odds Ratio | | | Odds Ratio | |
|--|-------------------------|-------|---------|-------|------------|---------------------|------|---------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | Year | M-H, Random, 95% Cl | |
| 1.10.1 Benralizumab | | | | | | | | | |
| Bleecker 2016 (SIROCCO) | 36 | 797 | 38 | 407 | 13.9% | 0.46 [0.29, 0.74] | 2016 | | |
| FitzGerald 2016 (CALIMA) | 34 | 480 | 17 | 248 | 12.3% | 1.04 [0.57, 1.89] | 2016 | | |
| Ferguson 2017 (BISE) | 0 | 0 | 0 | 0 | | Not estimable | 2017 | | |
| Nair 2017 (ZONDA) | 4 | 145 | 12 | 75 | 6.8% | 0.15 [0.05, 0.48] | 2017 | ← | |
| Subtotal (95% CI) | | 1422 | | 730 | 33.1% | 0.47 [0.20, 1.12] | | | |
| Total events | 74 | | 67 | | | | | | |
| Heterogeneity: Tau ² = 0.45; Chi ² = 9.58, df = 2 (P = 0.008); i ² = 79% | | | | | | | | | |
| Test for overall effect: Z = 1.71 | (P = 0.0) | 9) | | | | | | | |
| | | | | | | | | | |
| 1.10.2 Mepolizumab | | | | | | | | | |
| Flood-Page 2003 | 0 | 11 | 0 | 13 | | Not estimable | 2003 | | |
| Pavord 2012 (DREAM) | 27 | 461 | 17 | 155 | 11.9% | 0.51 [0.27, 0.95] | 2012 | | |
| Ortega 2014 (MENSA) | 56 | 385 | 23 | 191 | 13.4% | 1.24 [0.74, 2.09] | 2014 | | |
| Chupp 2017 (MUSCA) | 5 | 273 | 16 | 178 | 7.9% | 0.19 [0.07, 0.53] | 2017 | 4 | |
| Subtotal (95% CI) | | 1130 | | 537 | 33.2% | 0.53 [0.20, 1.42] | | | |
| Total events | 88 | | 56 | | | | | | |
| Heterogeneity: Tau" = 0.62; Chi" = 12.00, df = 2 (P = 0.002); I" = 83% | | | | | | | | | |
| Test for overall effect: Z = 1.28 | i (P = 0.2 ⁻ | 1) | | | | | | | |
| 1.10.3 Reslizumab | | | | | | | | | |
| Castro 2011 | 3 | 53 | 4 | 53 | 4.6% | 0.73 [0.16, 3.46] | 2011 | • • • • | |
| Castro 2015 (Study 1) | 11 | 245 | 17 | 244 | 10.3% | 0.63 [0.29, 1.37] | 2015 | | |
| Castro 2015 (Study 2) | 8 | 232 | 12 | 232 | 8.9% | 0.65 [0.26, 1.63] | 2015 | | |
| Bernstein 2020 (Study 1) | 12 | 234 | 12 | 230 | 9.8% | 0.98 [0.43, 2.23] | 2020 | | |
| Subtotal (95% CI) | | 764 | | 759 | 33.7% | 0.74 [0.47, 1.17] | | | |
| Total events | 34 | | 45 | | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 0.70, df = 3 (P = 0.87); l ² = 0% | | | | | | | | | |
| Test for overall effect: Z = 1.29 | (P = 0.2) | 0) | | | | | | | |
| Total (95% CI) | | 3316 | | 2026 | 100.0% | 0.59 [0.40, 0.88] | | | |
| Total events | 196 | | 168 | | | . , | | - | |
| Heterogeneity: Tau ² = 0.22 ^o Chi ² = 23.65 df = 9.09 ± 12 = 62% | | | | | | | | | |
| Test for overall effect: Z = 2.62 (P = 0.009) 0.2 0.5 1 2 | | | | | | | | | |
| Test for subgroup differences: Chi ² = 1.01, df = 2 (P = 0.60), l ² = 0% Favours Anti-IL-5 Favours Placebo | | | | | | | | | |

Fig. 11. ED or hospital admission for asthma exacerbation.

CRediT authorship contribution statement

Riccardo Giossi: Writing – original draft, Methodology, Formal analysis, Data curation, Conceptualization. **Arianna Pani:** Writing – review & editing, Data curation, Conceptualization. **Jan Schroeder:** Writing – review & editing, Conceptualization. **Francesco Scaglione:** Writing – review & editing, Supervision, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2023.e23725.

References

- C. Pelaia, G. Paoletti, F. Puggioni, F. Racca, G. Pelaia, G.W. Canonica, et al., Interleukin-5 in the pathophysiology of severe asthma, Front. Physiol. 10 (2019) 1514.
- [2] G.G. King, A. James, L. Harkness, P.A.B. Wark, Pathophysiology of severe asthma: we've only just started, Respirology. Australia 23 (2018) 262–271.
- [3] L.G. Heaney, L. Perez de Llano, M. Al-Ahmad, V. Backer, J. Busby, G.W. Canonica, et al., Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort, Chest. United States 160 (2021) 814–830.
- [4] R.L. Gieseck 3rd, M.S. Wilson, T.A. Wynn, Type 2 immunity in tissue repair and fibrosis, Nat Rev Immunol. England 18 (2018) 62–76.
- [5] W.B. Harley, M.J. Blaser, Disseminated coccidioidomycosis associated with extreme eosinophilia, Clin Infect Dis an Off Publ Infect Dis Soc Am. United States 18 (1994) 627–629.
- [6] S. Ueki, Y. Konno, M. Takeda, Y. Moritoki, M. Hirokawa, Y. Matsuwaki, et al., Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes, J. Allergy Clin. Immunol. 137 (2016) 258–267.

- [7] C.M. Percopo, K.D. Dyer, S.I. Ochkur, J.L. Luo, E.R. Fischer, J.J. Lee, et al., Activated mouse eosinophils protect against lethal respiratory virus infection, Blood 123 (2014) 743–752.
- [8] A.W. Lindsley, J.T. Schwartz, M.E. Rothenberg, Eosinophil responses during COVID-19 infections and coronavirus vaccination, J. Allergy Clin. Immunol. 146 (2020) 1–7.
- [9] M. Valverde-Monge, J.A. Cañas, B. Barroso, D. Betancor, L. Ortega-Martin, A. Gómez-López, et al., Eosinophils and chronic respiratory diseases in hospitalized COVID-19 patients, Front. Immunol. 12 (2021) 668074.
- [10] M.H. Rahimi-Rad, B. Asgari, N. Hosseinzadeh, A. Eishi, Eosinopenia as a marker of outcome in acute exacerbations of chronic obstructive pulmonary disease, Maedica (Buchar) 10 (2015) 10–13.
- [11] Y. Lin, J. Rong, Z. Zhang, Silent existence of eosinopenia in sepsis: a systematic review and meta-analysis, BMC Infect. Dis. 21 (2021) 471.
- [12] S.M. Poznanski, M. Mukherjee, N. Zhao, C. Huang, K. Radford, A.A. Ashkar, et al., Asthma exacerbations on benralizumab are largely non-eosinophilic, Allergy (2021) 375–379. Denmark.
- [13] M. Laviolette, D.L. Gossage, G. Gauvreau, R. Leigh, R. Olivenstein, R. Katial, et al., Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia, J. Allergy Clin. Immunol. 132 (2013) 1086–1096.e5.
- [14] M. Castro, S.E. Wenzel, E.R. Bleecker, E. Pizzichini, P. Kuna, W.W. Busse, et al., Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study, Lancet Respir Med. England 2 (2014) 879–890.
- [15] H.-S. Park, M.-K. Kim, N. Imai, T. Nakanishi, M. Adachi, K. Ohta, et al., A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan, Int Arch Allergy Immunol. Switzerland 169 (2016) 135–145.
- [16] J.M. FitzGerald, E.R. Bleecker, P. Nair, S. Korn, K. Ohta, M. Lommatzsch, et al., Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet (London, England) 388 (2016) 2128–2141. England.
- [17] E.R. Bleecker, J.M. FitzGerald, P. Chanez, A. Papi, S.F. Weinstein, P. Barker, et al., Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet (London, England) 388 (2016) 2115–2127. England.
- [18] G.T. Ferguson, J.M. FitzGerald, E.R. Bleecker, M. Laviolette, D. Bernstein, C. LaForce, et al., Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Respir Med. England 5 (2017) 568–576.
- [19] P. Nair, S. Wenzel, K.F. Rabe, A. Bourdin, N.L. Lugogo, P. Kuna, et al., Oral glucocorticoid-sparing effect of benralizumab in severe asthma, N Engl J Med. United States 376 (2017) 2448–2458.
- [20] P.L. Zeitlin, M. Leong, J. Cole, R.M. Mallory, V.H. Shih, R.F. Olsson, et al., Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial, J. Asthma Allergy 11 (2018) 181–192.
- [21] R.A.J. Panettieri, T. Welte, K.V. Shenoy, S. Korn, M. Jandl, E.M. Kerwin, et al., Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA), J. Asthma Allergy 13 (2020) 115–126.
- [22] T.W. Harrison, P. Chanez, F. Menzella, G.W. Canonica, R. Louis, B.G. Cosio, et al., Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial, Lancet Respir Med. England 9 (2021) 260–274.
- [23] P.T. Flood-Page, A.N. Menzies-Gow, A.B. Kay, D.S. Robinson, Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway, Am J Respir Crit Care Med. United States 167 (2003) 199–204.
- [24] P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, et al., Mepolizumab and exacerbations of refractory eosinophilic asthma, N. Engl. J. Med. 360 (2009) 973–984.
- [25] I.D. Pavord, S. Korn, P. Howarth, E.R. Bleecker, R. Buhl, O.N. Keene, et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet (London, England) 380 (2012) 651–659. England.
- [26] H.G. Ortega, M.C. Liu, I.D. Pavord, G.G. Brusselle, J.M. FitzGerald, A. Chetta, et al., Mepolizumab treatment in patients with severe eosinophilic asthma, N Engl J Med. United States 371 (2014) 1198–1207.
- [27] E.H. Bel, S.E. Wenzel, P.J. Thompson, C.M. Prazma, O.N. Keene, S.W. Yancey, et al., Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, N Engl J Med. United States 371 (2014) 1189–1197.
- [28] G.L. Chupp, E.S. Bradford, F.C. Albers, D.J. Bratton, J. Wang-Jairaj, L.M. Nelsen, et al., Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial, Lancet Respir Med. England 5 (2017) 390–400.
- [29] M. Castro, S. Mathur, F. Hargreave, L.-P. Boulet, F. Xie, J. Young, et al., Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study, Am J Respir Crit Care Med. United States 184 (2011) 1125–1132.
- [30] M. Castro, J. Zangrilli, M.E. Wechsler, E.D. Bateman, G.G. Brusselle, P. Bardin, et al., Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials, Lancet Respir Med. England 3 (2015) 355–366.
- [31] L. Bjermer, C. Lemiere, J. Maspero, S. Weiss, J. Zangrilli, M. Germinaro, Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study, Chest. United States 150 (2016) 789–798.
- [32] J. Corren, S. Weinstein, L. Janka, J. Zangrilli, M. Garin, Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts, Chest. United States 150 (2016) 799–810.
- [33] J.A. Bernstein, J.C. Virchow, K. Murphy, J.F. Maspero, J. Jacobs, Y. Adir, et al., Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo, Lancet Respir Med. England 8 (2020) 461–474.
- [34] J. Tversky, A.P. Lane, A. Azar, Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial, Clin Exp allergy J Br Soc Allergy Clin Immunol. England 51 (2021) 836–844.
- [35] T. Takabayashi, D. Asaka, Y. Okamoto, T. Himi, S. Haruna, N. Yoshida, et al., A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis, Am J Rhinol Allergy. United States 35 (2021) 861–870.
 [36] C. Bachert, J.K. Han, M.Y. Desrosiers, P. Gevaert, E. Heffler, C. Hopkins, et al., Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a
- randomized, placebo-controlled trial, J Allergy Clin Immunol. United States 149 (2022) 1309–1317.e12.
 M. Hassani, T. Tak, C. van Aalst, S. van Nederveen, K. Tesselaar, N. Vrisekoop, et al., Differential effects of short- and long-term treatment with mepolizumab on
- [37] M. Hassani, I. Tak, C. van Aalst, S. van Nederveen, K. Tesselaar, N. Vrisekoop, et al., Differential effects of short- and long-term freatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma, iScience 24 (2021) 102913.